Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Purple milkweed has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Cardenolides bind the same pump site that potassium occupies, so serum potassium sets how much binding a given cardenolide exposure produces. When potassium is low, the same amount of plant material has a larger effect on the pump. This makes potassium status a determinant of the risk profile rather than a benefit pairing. Anyone considering this plant should regard low potassium as the condition that turns a small exposure into a large one.
The pump that cardenolides act on is magnesium dependent, and low magnesium also drives renal potassium loss that cannot be corrected until magnesium is replaced. Low magnesium therefore shifts the same cardenolide exposure toward a stronger effect by two routes at once. This is context for risk, not a reason to combine the two.
Blocking the sodium-potassium pump raises intracellular sodium, which slows the sodium-calcium exchanger and leaves more calcium inside the cell. Higher calcium load amplifies the cardenolide effect on excitable tissue. Rapid calcium loading on top of cardenolide exposure is a recognised hazard in clinical toxicology.
Glycyrrhizin blocks the enzyme that protects the mineralocorticoid receptor from cortisol, which pushes sodium retention and potassium loss. Lower potassium then increases cardenolide binding at the pump. The two together move the same variable in the same direction, which is why this pairing is flagged rather than recommended.
Herbs that raise urine volume also raise electrolyte loss, potassium included, though dandelion carries some potassium of its own. Any downward pressure on potassium matters more than usual next to a cardenolide-bearing plant. The concern is the direction of the shift rather than a quantified effect.
Keeping potassium and magnesium in normal range removes the main amplifier of cardenolide effect. That is a correction of a risk factor, not a reason to use the plant. It does not make cardenolide exposure predictable, because plant content itself varies severalfold.
Nothing specific on file for Purple milkweed. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.